Article
Core binding factor acute myeloid leukaemia and c-KIT mutations.
Oncology reports - 1 May 2013
Riera Ludovica, Marmont Filippo, Toppino Daniela, Frairia Chiara, Sismondi Francesca, Audisio Ernesta, Di Bello Cristiana, D'Ardia Stefano, Di Celle Paola Francia, Messa Emanuela, Inghirami Giorgio, Vitolo Umberto, Pich Achille
Abstract excerpt
Core binding factor (CBF) acute myeloid leukaemia (AML) represents 5-8% of all AMLs and has a relatively favourable prognosis. However, activating c-KIT mutations are reported to be associated with higher risk of relapse and shorter survival. To verify the incidence and prognostic value of c-KIT mutations in CBF AML, we retrospectively analysed bone marrow samples of 23 consecutive adult patients with de novo CBF...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.